Health
Comparison of oral vs intravenous etoposide in the management of small‐cell lung cancer: A real‐world, population‐based study – MD Linx
MDLinx original journal summary on Lung Cancer, Pulmonology from The Clinical Respiratory Journal
For firstline treatment in smallcell lung cancer (SCLC), researchers assessed whether PO vs IV etoposide is useful in combination with a platinum agent (cisplatin/carboplatin) in this study including 2,066 patients with SCLC. Based on stage, patients were divided as limited disease and extensive disease. Route of etoposide administration, dose reductions and vital status was evaluated in chemotherapy naïve patients receiving one cycle of combination chemotherapy. Findings revealed similar overal…
-
General20 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Noosa News22 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business20 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General22 hours agoToo skewed, too gentlemanly | The Spectator Australia